Proteins in blood could provide early cancer warning 'by more than seven years'
Overall Reaction & Promise
- Many commenters are excited; a 7‑year lead time is seen as a “huge win” if it works in practice.
- The approach feels clearer and more testable than many cancer headlines; people hope it can be replicated or disproven quickly.
- Some imagine pairing very‑early detection with mRNA or other targeted treatments within the next decade.
Comparison to Existing Tests & Biomarkers
- This study focuses on protein biomarkers; existing commercial products (e.g., Galleri) mainly use cfDNA and DNA methylation patterns.
- Proteins are seen as a complementary signal that might boost sensitivity and specificity when combined with cfDNA.
- Longstanding markers like CA 19‑9 for pancreatic cancer are mentioned; posters note we’ve been hunting blood biomarkers for decades.
Cancer Types & Current Limits
- The cited paper reportedly found little evidence for pancreatic, thyroid, lip/oral, or melanoma cancers after multiple‑testing correction.
- Some mention Galleri’s claim to be relatively good at detecting aggressive cancers like pancreatic via cfDNA.
- Concerns arise about distinguishing lethal cancers from indolent ones that might never affect lifespan.
Screening Benefits vs Harms
- Repeated discussion of overdiagnosis: more detected cancers but unchanged mortality (e.g., thyroid, some skin and prostate cancers).
- False positives drive anxiety, invasive follow‑ups, and sometimes harmful treatment without survival benefit.
- Several refer to national systems (Netherlands, UK) that deliberately limit testing based on population‑level cost‑effectiveness and QALY‑style thresholds.
- Examples: mammography radiation risk; prostate cancer often managed conservatively, especially in older men; skepticism of full‑body MRI screening.
Actionability, Anxiety & Individual Stories
- Key questions: what can you do with a 7‑year warning, and is there treatment that early?
- Some argue lifestyle changes and earlier, targeted follow‑up imaging could be valuable; others fear years of nocebo, stress, and depression.
- Anecdotes: a blood donor flagged for elevated immunoglobulins is undergoing slow, cautious follow‑up; others describe scares from routine labs that ultimately meant nothing.
Insurance, Ethics & System Design
- US commenters worry about mandatory testing and insurer misuse, though others note current ACA rules limit health‑insurance discrimination while life/long‑term‑care remain exposed.
- Debate over whether cost‑driven test aversion in public systems reflects justified evidence‑based policy or simple rationing.
Data, Models & Future Outlook
- Some want broad, frequent testing to build longitudinal datasets and refine models; others stress that more data isn’t always good when medicine is noisy and incentives skewed.
- Consensus: this is an intriguing early step that must be proven to improve real‑world outcomes, not just earlier detection.